Hyprosha 500 Injection contains Hydroxyprogesterone acetate 500 mg, a synthetic progestogen used primarily for its potent progestational activity. This medication is indicated for the prevention of preterm birth in pregnant women with a history of spontaneous preterm delivery and for various gynecological conditions requiring progestogen therapy. Hydroxyprogesterone acts by mimicking the natural hormone progesterone, thereby maintaining pregnancy by reducing uterine contractions and promoting a suitable endometrial environment. It is administered via intramuscular injection, ensuring sustained release and systemic absorption. Hyprosha 500 Injection is also utilized in the management of amenorrhea, abnormal uterine bleeding due to hormonal imbalance, and as part of hormone replacement therapy in specific cases. The dosage and duration of treatment should be individualized based on clinical response and physician assessment. Contraindications include known hypersensitivity to hydroxyprogesterone or other progestogens, thromboembolic disorders, liver dysfunction, and undiagnosed vaginal bleeding. Common adverse effects may include injection site reactions, headache, nausea, and fluid retention. Caution is advised in patients with cardiovascular disease or a history of thromboembolism. Hyprosha 500 Injection should be used under strict medical supervision with regular monitoring to ensure safety and efficacy.